In December 2021 it was announced that Swiss firm Polyphor - structured around discovery and development of macrocycle drugs addressing high unmet medical needs - had merged with EnBiotix with the new entity renamed Spexis. With limited SBIR involvement, Boston-based Enbiotix since 2013 had functioned as an engineered antibiotics company deploying novel systems and synthetic biology technologies developed by Prof. James J. Collins, the Termeer Professor of Medical Engineering & Science Professor, Department of Biological Engineering, MIT. These technologies enable the development of both novel antibiotics and potentiators of existing antibiotics having the potential to transform their spectrum of activity and resistance profile. With drug-resistant and drug-tolerant infections rapidly becoming a global health crisis, EnBiotixs robust product pipeline had addressed a wide range of acute and chronic infections to significantly impact the lives of patients.
